Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as ...

Exact Sciences Corporation EXAS is well-poised to grow in the coming quarters, courtesy of the ongoing momentum in its Cologuard and Oncotype DX tests. The company continues to invest in its pipeline ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Exact Sciences (EXAS) one of those stocks right now? By taking a look at the ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

Exact Sciences Corporation posted solid Q1 2025 earnings with revenues up 11% year-on-year, driven by strong performance in screening and Precision Oncology segments. Despite the sequential revenue ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the twenty research firms that are covering the stock, Marketbeat reports. Two ...

News of an apparently impending sale to a strategic investor sent shares of Exact Sciences (NASDAQ: EXAS) skyward on Wednesday. The cancer diagnostics specialist's shares closed the day nearly 24% ...